Hylenex

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Contraindications 4 Dosage 5 Adverse-effects 6 Mechanism-of-action 7 More General Terms 8 Additional Terms 9 References

Introduction

• Tradenames: Wydase, Amphadase, Vitrase, Hydase, Hylenex (recominant)

Indications

• to increase the dispersion & absorption of other drugs
• increase the absorption of parenteral fluids given by hypodermoclysis
• enhance diffusion of locally irritating or toxic drugs in the management of IV extravasation

Contraindications

• Caution:
• 0.02 mL intradermal test dose for sensitivity prior to administration

Dosage

• management of IV extravasation

• reconstitute 150 unit vial of lyophylized powder with 1 mL of normal saline
• take 0.1 mL of this solution & dilute with 0.9 mL of normal saline to yield 15 units/ mL
• five 0.2 mL injections are made SC or intradermally into the extravasation site at the leading edge using a 25 or 26 gauge needle
• change needle after each injection

• hypodermoclysis

• add 15 units to each 200 mL of IV fluid to be administered by SC route
• children: limit volume of single clysis to 200 mL

• absorption & dispertion of drugs

• 150 units added to vehicle containing the drug

• Injection: ( lyophylized) 150 units
• Injection: (solution) 150 units/ mL (1 mL)
• Amphadase, Hydase ( bovine), Vitrase (ovine), Hylenex (human)

Adverse-effects

• uncommon (< 1%)

• tachycardia, hypotension, dizziness, urticaria, erythema, nausea/vomiting, chills

Mechanism-of-action

• hyaluronoglucosaminidase ( hyaluronidase)

More General Terms

• hyaluronoglucosaminidase; hyaluronidase (HYAL)
• metabolic agent (metabolic modifier)

Additional Terms

• intravenous (IV) extravasation

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
2. Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: [1] (subscription needed) [2]

Hylenex (Wydase, Amphadase, Vitrase, Hydase, hyaluronidase)